Chief Technology Officer
Gregg Nyberg is a biopharmaceutical executive with twenty-five years of experience in process development, clinical manufacturing, technology transfer and commercialization. He is currently Chief Technology Officer at Landmark Bio, where he is responsible for establishing process development and clinical manufacturing capabilities for emerging technologies such as cell and gene therapy. Prior to joining Landmark, Gregg served in multiple leadership roles at Merck, Amgen and Wyeth BioPharma/Genetics Institute. Most recently, Gregg was Head of Biologics Process Research & Development at Merck, where he was responsible for process development and clinical manufacturing of biologics drug substance. Gregg received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.